Ceva rapid growth expected to continue in 2013

Ceva Holdings, Inc. today affirmed its continued growth in 2013 for the North America market following the financial reporting results of its parent company, Ceva Santé Animale.

Ceva Holdings, Inc. affirmed its continued growth in 2013 for the North America market following the financial reporting results of its parent company, Ceva Santé Animale. The company completed its consolidation of its North America headquarters operations to the Lenexa, Kan., campus in late fall 2012. The move expanded the company workforce and has already resulted in better synergies to serve customers more efficiently for both its Ceva Animal Health and Ceva Biomune subsidiaries.
In 2012, Vectra parasiticide sales grew 34.5 percent in the US. Feliway and Adaptil continued to drive expansion of the behavior segment growing 30.4 percent. The company also entered the equine market in the United States with the launch of Altresyn (altrenogest).
In the avian market, Ceva captured the number two market position in 2012 after the successful conclusion of Ceva’s integration of Vetech Laboratories, a Canadian poultry vaccine manufacturer that markets live vaccines against coccidiosis. This allowed Ceva to add Vetech’s live coccidiosis vaccine Immucox T to the portfolio in the highly competitive United States market, expanding the poultry vaccine range from respiratory to also include intestinal health.
“We are coming off a very strong year and believe Ceva will continue growth with an outstanding team in place, with great existing and new products, and with continued financial support and commitment to the veterinary profession, “said Craig Wallace, Chief Executive Officer of Ceva Holdings, Inc.
Demonstrating Ceva’s commitment to grow its management team, Dr. Karen Padgett joined Ceva January 1 as Chief Operating Officer of the Ceva Animal Health Companion Animal Group. Padgett is a 28-year veteran of the animal health industry, most of which has been spent at Hill’s Pet Nutrition, a division of Colgate-Palmolive.
Upon being named to the position, Dr. Padgett said, “Ceva is a global company that is rapidly growing, but shows true commitment to the veterinary profession. I am thrilled to join the organization to lead a dynamic team and continue to contribute to the veterinary profession in a meaningful way. It’s a tremendous opportunity.”
The company plans to not only continue to market its products aggressively, but help educate pet owners to drive traffic to veterinary clinics. The Vectra brand will be supported in 2013 by a multi-media advertising campaign which includes television advertising and a "first dose free” coupon program.
The Feliway line will be extended with the introduction of new Feliway Wipes at the Western Veterinary Conference. Both Adaptil and Feliway will be supported by a major nationwide Behavior Advocate Program and veterinary exclusive trial generating consumer programs. In addition, the successful public relations bus tour will be expanded. The tour is aimed at increasing awareness that there are solutions to help keep pets from being put down due to unwanted behavior issues.
Ceva Animal Health has increased its visibility in the veterinary profession by joining in the celebration of the American Veterinary Medical Association’s 150th Anniversary as a sponsor. The company is also a sponsor of the One Health, One World initiative, is an inaugural sponsor of the American Association of Feline Practitioner’s Cat Practice initiative, and continues its commitment to educating veterinarians through conference CE and a new state veterinary medical association program.
Ceva Biomune’s $7 million renovation to its research and development facility in Lenexa announced in July 2012 is expected to be completed in June, 2013. The renovation will give the team 18,000 square feet of bio safety level 2 laboratory space and 15,000 square feet of office space. In May 2011, Ceva completed an $18 million expansion of its Biomune poultry vaccine production plant on the Ceva Biomune campus.
“Continued expansion of our research and manufacturing facilities is critical to meeting the needs of our domestic and global customers. We are on schedule to deliver on that investment and look forward to the opening of the renovated research and development facility,” said Daryl Pint, Chief Executive Officer of Ceva Biomune.
Page 1 of 61
Next Page